Delayed Wound Healing in Diabetes: Considering Future Treatments

Total Page:16

File Type:pdf, Size:1020Kb

Delayed Wound Healing in Diabetes: Considering Future Treatments REVIEW Delayed wound healing in diabetes: considering future treatments Thanh Dinh1, Sarah Elder1 & Aristidis Veves†1 Impaired wound healing and growth factors: ū The diabetic foot ulcer displays characteristics of a chronic wound with diminished expression of growth factors integral to healing, such as PDGF, FGF, VEGF, EGF, NGF and GM-CSF. Current therapies: ū The cornerstones of diabetic foot wound care include periodic debridement, adequate treatment of infection, treatment of ischemia, pressure off-loading and moist wound care. Practice Points Practice ū When standard wound care fails to heal the diabetic foot ulcer, adjunctive treatment with advanced therapies such as negative pressure wound therapy, topical growth factors, hyperbaric oxygen and living skin equivalents may be necessary. ū Adjuvant therapies have demonstrated equivocal effectiveness in scientific studies and judicious use of these modalities is encouraged, given their expense. Future therapies: ū Future therapies currently under investigation for the treatment of diabetic foot ulcers include platelet-rich plasma, stem cell therapy, extracorporeal shock-wave therapy, laser therapy and topical lactoferrin. SUMMARY Diabetic foot ulcers result from multiple risk factors including peripheral neuropathy, arterial insufficiency and foot deformities. Recent investigation has also revealed a chronic wound environment with diminished expression of growth factors and cytokines integral to the wound healing process. Current accepted standard of care for the treatment of diabetic foot ulcerations focuses on periodic debridement of the wound, appropriate topical wound therapy, pressure off-loading and treatment of infection. Owing to increased cost and equivocal effectiveness, topical growth factors, bioengineered living skin equivalents, hyperbaric oxygen therapy and negative pressure wound therapy are proposed as adjuncts to standard of care and may be added to the treatment regimen when healing of the wound has stalled. Other future therapies currently under investigation include stem cell therapy, platelet-rich plasma, extracorporeal shock-wave therapy and laser treatment. These modalities continue to be developed and tested, and may offer promise as effective therapies in the future for the chronic diabetic foot ulcer. 1Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA, USA †Author for correspondence: [email protected] 10.2217/DMT.11.44 © 2011 Future Medicine Ltd Diabetes Manage. (2011) 1(5), 509–519 ISSN 1758-1907 509 REVIEW Dinh, Elder & Veves Diabetic foot ulcerations will affect approxi- Impaired wound healing & growth factors mately 15% of all patients with diabetes, are Over the last decade, it has been recognized the leading cause of hospitalization among all that diabetes is a disease based fundamentally patients with diabetes, and are the most com- on inflammation. Both Type 1 and 2 diabetes mon risk factor for lower extremity amputa- are characterized by a nonsequential release of tion [1,2]. The physical, psychological and eco- pro- and anti-inflammatory cytokines, result- nomic burden of diabetic foot ulcerations is of ing in an imbalance that leads to impaired tis- paramount concern to the patient, the patient’s sue repair and weakened cellular and humoral family and the healthcare system. As a result, immune defense mechanisms [8,9]. great attention has been focused on the cause, The normal cascade of wound healing treatment and prevention of diabetic foot ulcers involves an orderly transition through three in the last decade. well-defined phases: inflammation, prolifera- Diabetic foot ulcers are the result of various tion and remodeling. Normal wound healing etiological factors and are characterized by an involves a timely progression through these three inability to self-repair in a timely and orderly phases, ultimately resulting in wound epitheliali- manner [3]. Etiological factors can be categorized zation. However, in the chronic wound such as into intrinsic (i.e., neuropathy, peripheral vas- the diabetic foot ulcer, the progression of heal- cular disease and diabetes severity) and extrin- ing is stalled in the initial inflammation phase sic (i.e., wound infection, callus formation and and resists further progression. Central to their excessive pressure to the site) causes [4]. poor healing, diabetic foot ulcers demonstrate a Studies have found that the pathway to foot decreased immune cell infiltration, with persist- ulceration begins with the presence of three ence of neutrophils and macrophages [10]. This distinct conditions: peripheral neuropathy, foot diminishment in inflammatory cell recruitment deformities, and acute or chronic repetitive ultimately results in alterations in growth factor trauma. The presence of peripheral neuropa- expression (Table 1). thy results in an insensate foot with structural It is well established that growth factors play deformity vulnerable to trauma. This trauma an integral role in the normal wound healing may be presented in the form of chronic pres- cascade, and their addition to the chronic wound sures from everyday activity or sudden acute may serve as a catalyst to healing [11]. Growth trauma from the environment such as ill-fitting factors influence the wound healing process foot wear or stepping on a foreign object [5–7]. both through inhibitory and stimulatory effect In addition to the triad of risk factors on the local wound environment. A multitude of described, impaired wound healing, character- growth factors are present in wound healing with ized by a chronic wound environment, has been the most prominent growth factors consisting of: implicated as another reason for poor healing PDGF, FGF, VEGF, EGF, NGF and GM-CSF. exhibited in diabetic foot ulcers. Recent inves- PDGF plays a major role in wound healing, tigation into impaired wound healing in these acting as a mitogen on fibroblasts, vascular chronic wounds has highlighted impairments smooth muscle cells, endothelial cells, neurons at the microvascular level as well as abnormal and macrophages, and as a chemotactic agent expression of growth factors and other cytokines for neutrophils, macrophages and fibroblasts. involved in the healing process. PDGF also enhances proliferation of fibroblasts, Table 1. Growth factors and their roles in normal wound healing. PDGF Mitogenic on fibroblasts, vascular smooth muscle cells, endothelial cells, neurons and macrophages. Enhances proliferation of fibroblasts, stimulates the production of extracellular matrix by these cells and triggers fibroblasts to acquire a myofibroblast phenotype FGF Stimulate angiogenesis, cell proliferation, regulate migration and differentiation of cells of mesodermal, ectodermal and endodermal origin EGF Regulates re-epithelialization and granulation tissue formation VEGF Major regulator of both vasculogenesis and angiogenesis GM-CSF Involved in angiogenesis and is mitogenic for keratinocytes NGF Essential for the development and survival of certain sympathetic and sensory neurons in both the CNS and PNS 510 Diabetes Manage. (2011) 1(5) future science group Delayed wound healing in diabetes: considering future treatments REVIEW stimulates the production of extracellular matrix Wound debridement by these cells and triggers fibroblasts to acquire Debridement of the wound incorporates the a myofibroblast phenotype [12,13]. concept of wound bed preparation by control- FGFs typically stimulate cell proliferation, ling exudate and edema, decreasing bacterial regulate migration and differentiation of cells burden, promoting healthy granulation tis- of mesodermal, ectodermal and endodermal sue and removing necrotic tissue [19,20]. Over origin. FGFs are mitogenic for several cell types the last decade, the significance of wound bed present at the wound site, including fibroblasts preparation has evolved, given its multiple and keratinocytes [14]. Finally, both FGF1 and roles in wound healing. The role of wound bed FGF2 stimulate angiogenesis [15]. preparation has been described as a dynamic EGF plays an important role in re-epitheli- concept, involving a balance between aggres- alization and granulation tissue formation. It sive and repeated removal of all necrotic tis- has been shown to be mitogenic for fibroblasts sue followed by timely evaluation and tissue and keratinocytes. VEGF has been identified management [21]. as a major regulator of both vasculogenesis Wound bed preparation can be performed and angiogenesis, and its levels increase during through a variety of methods including sharp trauma and ischemia [16]. VEGF also serves to debridement, low-frequency ultrasound and stimulate wound angiogenesis in a paracrine enzymatic debriders. Sharp debridement is manner. NGF is essential for the development considered the gold standard as the operator and survival of certain sympathetic and sensory can visually identify the depth and extent of neurons in both the CNS and PNS. GM-CSF tissue that needs to be removed. It can be per- is involved in a ngiogenesis and is mitogenic formed in the office setting in an insensate foot for keratinocytes. with a variety of instruments, with the most The number of growth factors identified in c ommonly used being the scalpel blade. the normal wound healing process continues to However, when a sensate limb cannot tolerate be elucidated, offering further information on sharp debridement, other methods of wound how the chronic wound differs from a wound bed preparation must be explored. A novel that goes on to
Recommended publications
  • Wound Bed Preparation: TIME in Practice
    Clinical PRACTICE DEVELOPMENT Wound bed preparation: TIME in practice Wound bed preparation is now a well established concept and the TIME framework has been developed as a practical tool to assist practitioners when assessing and managing patients with wounds. It is important, however, to remember to assess the whole patient; the wound bed preparation ‘care cycle’ promotes the treatment of the ‘whole’ patient and not just the ‘hole’ in the patient. This paper discusses the implementation of the wound bed preparation care cycle and the TIME framework, with a detailed focus on Tissue, Infection, Moisture and wound Edge (TIME). Caroline Dowsett, Heather Newton dependent on one another. Acute et al, 2003). Wound bed preparation wounds usually follow a well-defined as a concept allows the clinician to KEY WORDS process described as: focus systematically on all of the critical Wound bed preparation 8Coagulation components of a non-healing wound to Tissue 8Inflammation identify the cause of the problem, and Infection 8Cell proliferation and repair of implement a care programme so as to Moisture the matrix achieve a stable wound that has healthy 8Epithelialisation and remodelling of granulation tissue and a well vascularised Edge scar tissue. wound bed. In the past this model of healing has The TIME framework been applied to chronic wounds, but To assist with implementing the he concept of wound bed it is now known that chronic wound concept of wound bed preparation, the preparation has gained healing is different from acute wound TIME acronym was developed in 2002 T international recognition healing. Chronic wounds become ‘stuck’ by a group of wound care experts, as a framework that can provide in the inflammatory and proliferative as a practical guide for use when a structured approach to wound stages of healing (Ennis and Menses, managing patients with wounds (Schultz management.
    [Show full text]
  • Understand Your Chronic Wound
    Patient Information Leaflet Understanding your Chronic Wound Dressings, management and wound infection In this leaflet Health Care Professional (HCP) refers to any member of the team involved in your wound care. This can include treatment room or practice nurse, community, ward or clinic nurse, GP or hospital doctor, podiatrist etc. Chronic Wounds and Dressings What is a Chronic wound? A wound with slow progress towards healing or shows delayed healing. This may be due to underlying issues such as: • Poor blood flow and less oxygen getting to the wound • Other health conditions • Poor diet, smoking, pressure on the wound e.g. footwear/seating. Can my wound be left open to the air? No, the evidence shows that wounds heal better when the surface is kept moist (not too wet or dry). The moisture provides the correct environment to aid your wound to heal. Does my dressing need changed daily? Not usually, your HCP will explain how often it needs changed. This will depend on the level of fluid leaking from your wound. Some dressings can be left in place up to a week. Most wounds have a slight odour, but if a wound smells bad it could be a sign that something is wrong. See section on wound infection. Your dressing may indicate that it needs changed when the dark area in the centre gets close to the edge of the dressing pad. The dark area is fluid from your wound, this is normal. It will be dry to touch. Let your HCP know if your dressing needs changed before your next visit or appointment is due.
    [Show full text]
  • Guideline: Wound Bed Preparation for Healable and Non Healable Wounds
    British Columbia Provincial Nursing Skin and Wound Committee Guideline: Wound Bed Preparation for Healable and Non Healable Wounds Developed by the BC Provincial Nursing Skin and Wound Committee in collaboration with Wound Clinicians from: / TITLE Guideline: Wound Bed Preparation for Healable and Non-Healable Wounds in Adults & Children1 Practice Level Nurses in accordance with health authority and agency policy. Conservative sharp wound debridement (CSWD) is a restricted activity according to the Nurse’s (Registered) and Nurse Practitioner Regulation. 2 CRNBC states that registered nurses must successfully complete additional education and follow an established guideline when carrying out CSWD. Biological debridement therapy is a restricted activity according to the Nurse’s (Registered) and Nurse Practitioner Regulation. 3 CRNBC states that registered nurses must follow an established guideline when carrying out biological debridement. Clients 4 with wounds needing wound bed preparation require an interprofessional approach to provide comprehensive, evidence-based assessment and treatment. This clinical practice guideline focuses solely on the role of the nurse, as one member of the interprofessional team providing care to these clients. Background Factors affecting wound healability include the presence of adequate circulation in the area of the wound, wound related factors such as the size and duration of the wound, the ability to treat the cause of the wound and the presence of risk factors impacting wound healing. While many wounds heal, others are determined to be non-healing or slow-to-heal based on the presence or absence of these factors. Wound healability must be determined prior to debridement and moist wound healing. Although wound healing normally occurs in a predictable fashion, wound healing trajectories can be heterogeneous and non- uniform resulting is delayed wound healing for some clients.
    [Show full text]
  • Reactive Oxygen Species (ROS)
    EuropeanN Bryan etCells al. and Materials Vol. 24 2012 (pages 249-265) Reactive DOI: 10.22203/eCM.v024a18oxygen species in inflammation and ISSN wound 1473-2262 healing REACTIVE OXYGEN SPECIES (ROS) – A FAMILY OF FATE DECIDING MOLECULES PIVOTAL IN CONSTRUCTIVE INFLAMMATION AND WOUND HEALING Nicholas Bryan1*, Helen Ahswin2, Neil Smart3, Yves Bayon2, Stephen Wohlert2 and John A. Hunt1 1Clinical Engineering, UKCTE, UKBioTEC, The Institute of Ageing and Chronic Disease, University of Liverpool, Duncan Building, Daulby Street, Liverpool, L69 3GA, UK 2Covidien – Sofradim Production, 116 Avenue du Formans – BP132, F-01600 Trevoux, France 3Royal Devon & Exeter Hospital, Barrack Road, Exeter, Devon, EX2 5DW, UK Abstract Introduction Wound healing requires a fine balance between the positive The survival and longevity of any animal requires an active and deleterious effects of reactive oxygen species (ROS); vigilant set of defence mechanisms to combat infection, a group of extremely potent molecules, rate limiting in efficiently repair damaged tissue and remove debris successful tissue regeneration. A balanced ROS response associated with apoptotic/necrotic cells. Compromised will debride and disinfect a tissue and stimulate healthy tissue rapidly results in decreased mobility, organ failures, tissue turnover; suppressed ROS will result in infection hypovolaemia, hypermetabolism, and ultimately infection and an elevation in ROS will destroy otherwise healthy and sepsis. Therefore, mammals have evolved an array stromal tissue. Understanding and anticipating the ROS of physiological pathways and mechanisms that enable niche within a tissue will greatly enhance the potential to damaged tissue to return to a basal homeostatic state. In exogenously augment and manipulate healing. an ideal scenario this occurs without compromise of tissue Tissue engineering solutions to augment successful mechanics, scarring or incorporation of microbial material.
    [Show full text]
  • The Role of Antioxidants on Wound Healing: a Review of the Current Evidence
    Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 15 July 2021 doi:10.20944/preprints202107.0361.v1 Review THE ROLE OF ANTIOXIDANTS ON WOUND HEALING: A REVIEW OF THE CURRENT EVIDENCE. Inés María Comino-Sanz 1*, María Dolores López-Franco1, Begoña Castro2, Pedro Luis Pancorbo-Hidalgo1 1 Department of Nursing, Faculty of Health Sciences, University of Jaén, 23071 Jaén (Spain); [email protected] (IMCS); MDLP ([email protected]); PLPH ([email protected]). 2 Histocell S.L., Bizkaia Science and Technology Park, Derio, Bizkaia (Spain); [email protected] * Correspondence: [email protected]; Tel.: +34-953213627 Abstract: (1) Background: Reactive oxygen species (ROS) play a crucial role in the preparation of the normal wound healing response. Therefore, a correct balance between low or high levels of ROS is essential. Antioxidant dressings that regulate this balance is a target for new therapies. The pur- pose of this review is to identify the compounds with antioxidant properties that have been tested for wound healing and to summarize the available evidence on their effects. (2) Methods: A litera- ture search was conducted and included any study that evaluated the effects or mechanisms of an- tioxidants in the healing process (in vitro, animal models, or human studies). (3) Results: Seven compounds with antioxidant activity were identified (Curcumin, N-acetyl cysteine, Chitosan, Gallic Acid, Edaravone, Crocin, Safranal, and Quercetin) and 46 studies reporting the effects on the healing process of these antioxidants compounds were included. (4) Conclusions: These results highlight that numerous novel investigations are being conducted to develop more efficient systems for wound healing activity. The application of antioxidants is useful against oxidative damage and ac- celerates wound healing.
    [Show full text]
  • Venous Ulcer Assessment and Management: Using the Updated CEAP Classification System
    Practice Points Venous Ulcer Assessment and Management: Using the Updated CEAP Classification System Cathy Thomas Hess, BSN, RN, CWCN ylastcolumn,Classification of Pressure Injuries, Although most leg ulcers are venous ulcers, the clini- discussed the importance of documenting the cian should suspect other causes when the wound looks details of pressure injuries using the updated atypical (presence of necrotic tissue, exposed tendon, M pressure injury classification system. This livedo reticularis on surrounding skin, or a deep, column discusses the updated classification system for “punched-out” ulcer), has been present for longer than venous ulcers, namely, the Clinical Etiology Anatomy 6 months, or has not responded to good care. Do not Pathophysiology (CEAP) classification system. To under- hesitate to take a biopsy when in doubt. stand the use of this classification, let’sbrieflydiscussthe Visual and palpable assessment may not be enough etiology, assessment, and management of venous ulcers. to determine the next steps. Objective testing may be needed to confirm the diagnosis, determine the etiology ETIOLOGY of the problem, and identify the anatomic site and sever- Venous ulcers are believed to account for approximately ity of disease pathway (Table). 70% to 90% of chronic leg ulcers.1 The incidence of ve- nous ulceration increases with age, and women are three times more likely than men to develop venous leg ulcers.2 Table. CLINICAL FINDINGS ASSOCIATED WITH VENOUS In some studies, 50% of patients had venous ulcers that LEG ULCERS persisted for more than 9 months, and 20% had ulcers Wound location 30%–40% occur superior to the medial malleolus (near the that did not heal for more than 2 years.
    [Show full text]
  • Products & Technology Wound Inflammation and the Role of A
    Products & technology Wound inflammation and the role of a multifunctional polymeric dressing Temporary inflammation is a normal response in acute wound healing. However, in chronic wounds, the inflammatory phase is dysfunctional in nature. This results in delayed healing, and causes further problems such as increased pain, odour and Intro high levels of exudate production. It is important to choose a dressing that addresses all of these factors while meeting the patient’s needs. Multifunctional polymeric Authors: Keith F Cutting membrane dressings (e.g. PolyMem®, Ferris) can help to simplify this choice and Authors: Peter Vowden assist healthcare professionals in chronic wound care. The unique actions of xxxxx Cornelia Wiegand PolyMem® have been proven to reduce and prevent inflammation, swelling, bruising and pain to promote rapid healing, working in the deep tissues beneath the skin[1,2]. he mechanism of acute wound healing — the vascular and cellular stages. During is a well-described complex cellular vascular response, immediately on injury there is T interaction[3] that can be divided into an initial transient vasoconstriction that can be several integrated processes: haemostasis, measured in seconds. This is promptly followed inflammation, proliferation, epithelialisation by vasodilation under the influence of histamine and tissue remodeling. Inflammation is a key and nitric oxide (NO) that cause an inflow of blood. component of acute wound healing, clearing An increase in vascular permeability promotes damaged extracellular matrix, cells and debris leakage of serous fluid (protein-rich exudate) into from zones of tissue damage. This is normally a the extravascular compartment, which in turn time-limited orchestrated process. Successful increases the concentration of cells and clotting progression of the inflammatory phase allows factors.
    [Show full text]
  • Peripheral Arterial Occlusive Disease
    Peripheral Arterial Occlusive Disease - ACOI Chicago Hospitalist Meeting Davin Haraway DO,FACOI,FACCWS,RPhS Diplomate – American Board of Venous and Lymphatic Medicine Arterial Issues – Lower extremity encountered by Hospitalists • Acute arterial occlusion • More commonly however • Chronic peripheral vascular disease and manifestations • Ulcers toes, heels,ankles, legs, • Infected ulcers • Cellulitis • Diabetic foot ulcers • Claudication • Edema • Calciphylaxis • Non healing surgical wounds including , BKA,AKA,foot and ankle procedures, • Differentiating from Gout and Charcot Foot Atheroma Prevalence • Dx of PAD ranges from 1–22%, depending on population, risk factors, diagnostic tests • Asymptomatic PAD up to 6 times more common than symptomatic PAD • 8.4 million Americans >40 years old have PAD • High overlap of PAD with CAD and CVD • Prevalence of PAD in persons >70 years 5 times greater than in persons <40 years • Claudication 3-4 times more common in diabetics and 3 times more common in smokers Peripheral Arterial Disease and Intermittent Claudication • Peripheral Arterial Disease (PAD) A disorder caused by atherosclerosis that limits blood flow to the limbs. • Intermittent Claudication (IC) A symptom of PAD characterized by pain, aching, or fatigue in working skeletal muscles. IC arises when there is insufficient blood flow to meet the metabolic demands in leg muscles of ambulating patients. Pathophysiology of Intermittent Claudication • Intermittent claudication is associated with – Metabolic abnormalities stemming from reduced 1 blood flow and O2 delivery – Significant reduction (50%) in muscle fibers compared with controls2 – Smaller type I and II muscle fibers with greater arterial ischemia2 – Hyperplastic mitochondria and demyelination of nerve fibers3 1 Lundgren et al Am J Physiol. 1988;255:H1156-64.
    [Show full text]
  • Wound Bed Preparation in Practice
    POSITION DOCUMENT Wound bed preparation in practice Wound bed preparation: science applied to practice Wound bed preparation for diabetic foot ulcers Wound bed preparation for venous leg ulcers MANAGING EDITOR Suzie Calne SENIOR EDITORIAL ADVISOR Christine Moffatt Professor and Co-director, Centre for Research and Implementation of Clinical Practice, Wolfson Institute of Health Sciences, Thames Valley University, London, UK CONSULTANT EDITOR Madeleine Flanagan Principal Lecturer, Department of Continuing Professional Development, Faculty of Health and Human Sciences, University of Hertfordshire, UK EDITORIAL ADVISORS Vincent Falanga Professor of Dermatology and Biochemistry, Boston University; Chairman and Training Program Director, Roger Williams Medical Centre, Providence, Rhode Island, USA Marco Romanelli Consultant Dermatologist, Department of Dermatology, University of Pisa, Italy J Javier Soldevilla Ágreda Professor of Geriatric Care, EUE University of La Rioja, Logroño, Spain Supported by an educational Luc Téot grant from Smith & Nephew. Assistant Professor of Surgery, University Hospital, Montpellier, France Peter Vowden Consultant in General Surgery, Department of Vascular Surgery, Bradford Royal Infirmary, UK Ulrich E Ziegler The views expressed in this Senior Consultant and Plastic Surgeon, Department of Plastic and Hand Surgery, University of publication are those of the Wuerzburg, Germany authors and do not necessarily reflect those of Smith & Nephew. EDITORIAL PROJECT MANAGER Kathy Day SUB-EDITOR Ann Shuttleworth DESIGNER
    [Show full text]
  • Chronic Venous Ulcers: a Comparative Effectiveness Review of Treatment Modalities Comparative Effectiveness Review Number 127
    Comparative Effectiveness Review Number 127 Chronic Venous Ulcers: A Comparative Effectiveness Review of Treatment Modalities Comparative Effectiveness Review Number 127 Chronic Venous Ulcers: A Comparative Effectiveness Review of Treatment Modalities Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 540 Gaither Road Rockville, MD 20850 www.ahrq.gov Contract No. 290-2007-10061-I Prepared by: Johns Hopkins University Evidence-based Practice Center Baltimore, MD Investigators Jonathan Zenilman, M.D. M. Frances Valle, D.N.P., M.S. Mahmoud B. Malas, M.D., M.H.S. Nisa Maruthur, M.D., M.H.S. Umair Qazi, M.P.H. Yong Suh, M.B.A., M.Sc. Lisa M. Wilson, Sc.M. Elisabeth B. Haberl, B.A. Eric B. Bass, M.D., M.P.H. Gerald Lazarus, M.D. AHRQ Publication No. 13(14)-EHC121-EF December 2013 Erratum January 2014 This report is based on research conducted by the Johns Hopkins University Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. 290-2007-10061-I). The findings and conclusions in this document are those of the author(s), who are responsible for its contents; the findings and conclusions do not necessarily represent the views of AHRQ. Therefore, no statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services. The information in this report is intended to help health care decisionmakers—patients and clinicians, health system leaders, and policymakers, among others—make well-informed decisions and thereby improve the quality of health care services.
    [Show full text]
  • Chronic Venous Leg Ulc Treatment: Future Er Research Needs
    Future Research Needs Paper Number 34 Chronic Venous Leg Ulcer Treatment: Future Research Needs Future Research Needs Paper Number 34 Chronic Venous Leg Ulcer Treatment: Future Research Needs Identification of Future Research Needs From Comparative Effectiveness Review No. 127 Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 540 Gaither Road Rockville, MD 20850 www.ahrq.gov Contract No. 290-2007-10061-I Prepared by: Johns Hopkins University Evidence-based Practice Center Baltimore, MD Investigators: Gerald Lazarus, M.D. Fran Valle, D.N.P., M.S., C.R.N.P. Mahmoud Malas, M.D., M.H.S. Umair Qazi, M.D., M.P.H. Nisa Maruthur, M.D., M.H.S. Jonathan Zenilman, M.D. Chad Boult, M.D., M.P.H., M.B.A. David Doggett, Ph.D. Oluwakemi A. Fawole, M.B.C.H.B., M.P.H. Eric B. Bass, M.D., M.P.H. AHRQ Publication No. 13(14)-EHC034-EF November 2013 Addendum added January 2014 Addendum to Future Research Needs Report for Chronic Venous Leg Ulcer Treatment This report was posted for public comment from November 4, 2013 to December 2, 2013 on the Effective Health Care Web site. We received one set of thoughtful comments from the American Physical Therapy Association. The comments were related to gaps outside the scope of the original systematic review and included: the role of exercise to optimize venous pump function, optimization of general fluid balance, occupational strategies to minimize edema, inclusion of strategies for debridement and predisposing factors for venous ulcers which are located at the level of the malleoli and above.
    [Show full text]
  • Skin Substitutes for Treating Chronic Wounds: Technical Brief
    Technology Assessment Program Skin Substitutes for Treating Chronic Wounds Technical Brief Project ID: WNDT0818 February 2, 2020 Technology Assessment Program - Technical Brief Project ID: WNDT0818 Skin Substitutes for Treating Chronic Wounds Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov Contract No. HHSA 290-2015-00005-I Prepared by: ECRI Institute - Penn Medicine Evidence-Based Practice Center Plymouth Meeting / Philadelphia, PA Investigators: D. Snyder, Ph.D. N. Sullivan, B.A. D. Margolis, M.D., Ph.D. K. Schoelles, M.D., S.M. ii Key Messages Purpose of Review To describe skin substitute products commercially available in the United States used to treat chronic wounds, examine systems used to classify skin substitutes, identify and assess randomized controlled trials (RCTs), and suggest best practices for future studies. Key Messages • We identified 76 commercially available skin substitutes to treat chronic wounds. The majority of these do not contain cells and are derived from human placental membrane (the placenta’s inner layer), animal tissue, or donated human dermis. • Included studies (22 RCTs and 3 systematic reviews) and ongoing clinical trials found during our search examine approximately 25 (33%) of these skin substitutes. • Available published studies rarely reported whether wounds recurred after initial healing. Studies rarely reported outcomes important to patients, such as return of function and pain relief. • Future studies may be improved by using a 4-week run-in period before study enrollment and at least a 12-week study period. They should also report whether wounds recur during 6-month followup.
    [Show full text]